A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102)

A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102) - A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043918

Enrollment

300

Registered

2021-04-14

Start date

2021-04-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients over 20 years old 2) Patients who can consent to documents 3) Patients diagnosed with advanced / recurrent non-small cell lung cancer or advanced / recurrent small cell lung cancer 4) Patients who are receiving or will be receiving cancer drug therapy 5) Patients scheduled to receive SARS-CoV-2 vaccine

Exclusion criteria

Exclusion criteria: 1) Patients with a history of developing COVID-19 2) Patients with a history of SARS-CoV-2 vaccination 3) Patients who think that it is inappropriate for their doctor to inoculate SARS-CoV-2 vaccine 4) Patients with an estimated prognosis within 2 months

Design outcomes

Primary

Measure	Time frame
Frequency of adverse reactions for 7 days after SARS-CoV-2 vaccination	—

Secondary

Measure	Time frame
Frequency of Grade 3 or higher irAE after SARS-CoV-2 vaccination in patients receiving immune checkpoint inhibitors	—

Countries

Japan

Contacts

Public ContactToshio Kubo

Okayama University Hospital Clinical Cancer Center

t-kubo@cc.okayama-u.ac.jp086-235-7227

Outcome results